Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

BACKGROUND: We determined whether the market exclusivity incentive of the European Orphan Drug Regulation results in a market monopoly or that absence of another Orphan Medicinal Product (OMP) for the same rare disorder, a so-called follow-on OMP, is a matter of time or market size. In the interest...

Descripción completa

Detalles Bibliográficos
Autores principales: Brabers, Anne EM, Moors, Ellen HM, van Weely, Sonja, de Vrueh, Remco LA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185263/
https://www.ncbi.nlm.nih.gov/pubmed/21892964
http://dx.doi.org/10.1186/1750-1172-6-59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185263/
https://www.ncbi.nlm.nih.gov/pubmed/21892964
http://dx.doi.org/10.1186/1750-1172-6-59

Ejemplares similares